
Bausch Health Companies Inc. (NYSE:BHC) on Tuesday agreed to indirectly acquire DURECT Corp (NASDAQ:DRRX), including a novel therapeutic molecule, larsucosterol.
Larsucosterol, an endogenous sulfated oxysterol and an epigenetic modulator, has demonstrated promising results for alcoholic hepatitis (AH) in Phase 2 trials.